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Abstract
Amyotrophic lateral sclerosis (ALS) is a poor-prognosis disease with puzzling pathogenesis
and inconclusive treatments. We develop a mathematical model of ALS based on a system
of interactive feedback loops, focusing on the mutant SOD1G93A mouse. Misfolded mutant
SOD1 aggregates in motor neuron (MN) mitochondria and triggers a first loop characterized
by oxidative phosphorylation impairment, AMP kinase over-activation, 6-phosphofructo-2-
kinase (PFK3) rise, glucose metabolism shift from pentose phosphate pathway (PPP) to gly-
colysis, cell redox unbalance, and further worsening of mitochondrial dysfunction. Oxidative
stress then triggers a second loop, involving the excitotoxic glutamatergic cascade, with
cytosolic Ca2+ overload, increase of PFK3 expression, and further metabolic shift from PPP
to glycolysis. Finally, cytosolic Ca2+ rise is also detrimental to mitochondria and oxidative
phosphorylation, thus closing a third loop. These three loops are overlapped and positive
(including an even number of inhibitory steps), hence they form a candidate multistationary
(bistable) system. To describe the system dynamics, we model the interactions among the
functional agents with differential equations. The system turns out to admit two stable equi-
libria: the healthy state, with high oxidative phosphorylation and preferential PPP, and the
pathological state, with AMP kinase activation, PFK3 over expression, oxidative stress,
excitotoxicity and MN degeneration. We demonstrate that the loop system is monotone: all
functional agents consistently act toward the healthy or pathological condition, depending
on low or high mutant SOD1 input. We also highlight that molecular interactions involving
PFK3 are crucial, as their deletion disrupts the system’s bistability leading to a single healthy
equilibrium point. Hence, our mathematical model unveils that promising ALS management
strategies should be targeted to mechanisms that keep low PFK3 expression and activity
within MNs.
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Introduction
Neurodegenerative diseases are progressive neuronal death syndromes characterized by apo-
ptosis and necrosis processes. In amyotrophic lateral sclerosis (ALS), these events involve
upper and lower motor neurons (MNs) at cortical, brainstem, and spinal levels, followed by
muscle weakness and paralysis. This syndrome is part of a series of MN diseases that also
includes pseudobulbar and progressive bulbar palsy, progressive muscular atrophy, and pri-
mary lateral sclerosis [1]. It is a complex and heterogeneous condition lacking established
early markers, which makes its diagnosis challenging and essentially based on clinical evidence
[2]. The disease has a poor prognosis, patients dying within 3–5 years since diagnosis, and the
only approved drugs are the anti-excitotoxic riluzole and the free-radical scavenger edaravone
[3].
Two different forms of ALS are known, familial and sporadic, with the former representing
about 5–10% of total cases [4]. A number of genes potentially involved in familial ALS have
been identified, with about 25% of these forms being due to mutations in the gene encoding
for Cu/Zn superoxide dismutase type 1 (SOD1). Among these latter, the most abundant one is
the glycine substitution with alanine at position 93 (G93A). Following this kind of evidence, a
mouse strain expressing SOD1G93A protein has been developed and widely adopted as an
experimental animal model in ALS molecular and preclinical studies [5].
A number of molecular mechanisms concerning MN degeneration in ALS have been
described, among which major topics include glutamate excitotoxicity, structural and func-
tional disorders of mitochondria, impaired axonal functions, protein misfolding linked to
endoplasmic reticulum stress, and oxidative stress [6–10]. Also, the involvement of cell types
other than MNs in the onset and progression of the disease has been documented, mostly
astrocytes, microglia, and oligodendrocytes, leading to the concept of non-cell autonomous
pathogenesis [11–13]. However, it is generally assumed that MNs are the site of disease onset,
while glial cells are believed to influence the disease by shifting from a homeostatic role to
aberrant reactivity that speeds up neuronal degeneration [14, 15].
The main hindrance to the development of effective treatments for ALS is the poor knowl-
edge of pathogenetic mechanisms. Despite a bulk of data collected through years at the molec-
ular, cellular, and organism levels, on both animal models and human subjects, and a number
of hypotheses put forward about pathogenesis, the identification of a bona fide primary event
for the onset of the disease is still lacking, thus making pharmacological and clinical strategies
disappointedly weak [16]. By considering previous published data from our laboratory [17,
18], as well as, at present, unpublished data, and combining them with other inputs from liter-
ature, in this study we propose a model based on interactive feedback loops mainly focused on
the SOD1G93A mouse model. In particular, we envisage a feedback loop interaction between
mitochondria and glucose metabolism in MNs. Such a model provides hints for a description
of ALS insurgence in terms of a multistationary system driven by positive loops, i.e. chains of
interactions that are overall activating, which undergoes transitions among different equilib-
rium points or steady-state configurations [19].
The model
Biological background
We started from the obvious consideration that mutant SOD1 protein must have an essential
role in pathogenesis. A clue for an interpretation of this role is offered by functional and pro-
apoptotic degeneration of mitochondria observed in spinal cord MNs, starting from pre-
symptomatic stages of the disease [17, 20]. These data can be linked to the finding that ALS
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mutant SOD1 forms aggregates of misfolded units specifically on the outer membrane of spi-
nal MN mitochondria, eventually impairing mitochondrial function [21, 22]. This event can
play a seminal role in the onset of the disease, considering that in the central nervous system
(CNS) the energetic metabolism is distinctly partitioned, with astrocytes being more glycolytic
and neurons more oxidative, involving higher energy metabolism via oxidative phosphoryla-
tion (OXPHOS) in neurons. Moreover, neurons also display a high rate of the pentose phos-
phate pathway (PPP), while astrocytes are known to provide neurons with lactate that is then
converted to pyruvate and contributes to satisfy the needs for mitochondrial metabolism [23,
24]. Given these premises, another important piece of evidence for the building of our model
is the apparent inversion of MN energetic metabolism in SOD1G93A mice, from prevalently
oxidative under healthy conditions to prevalently glycolytic during pathogenesis [17, 18].
Moreover, as observed for mutant SOD1 binding to mitochondria, also the metabolism inver-
sion occurs in the spinal cord at an early stage of the disease and then appears in the motor
cortex at a later symptomatic stage [18].
Consistent with the mitochondrial impairment induced by mutant SOD1, a decreased
ATP/AMP ratio has been found in spinal cord MNs in SOD1G93A mice already at pre-symp-
tomatic stages [17]. As known, the AMP accumulation promotes the activity of the energy sen-
sor AMP-activated kinase (AMPK) [25] and, consistently, abnormally upregulated AMPK has
been reported for both SOD1G93A mice and ALS patients [26]. Moreover, the antidiabetic drug
metformin, which is known to activate AMPK [27], has been found to accelerate both symp-
tom onset and disease progression in SOD1G93A mice [28]. As a consequence, these data lead
directly to glucose catabolism as a major player in the disease.
Glycolysis is known to be controlled by the enzyme 6-phosphofructo-1-kinase, which is
regulated allosterically by fructose-2,6-bisphosphate. In the brain, the biosynthesis of the latter
is operated almost exclusively by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3
(PFK3) that is activated through phosphorylation by AMPK [29]. In normal neurons, glycoly-
sis is low, due to limited PFK3 activity, in favor of an elevated PPP rate [24]. Hence, it could be
argued that in MNs developing ALS an increase of AMPK activity would lead to PFK3 activa-
tion, thereby producing a shift of glucose catabolism, from PPP to glycolysis [23]. Now, being
PPP the major producer of reducing equivalents in the cell, such a shift would be detrimental
for the cell redox balance, thus exacerbating an already compromised scenario characterized
by mitochondrial dysfunction and the correlated increase of oxidative stress. In fact, mito-
chondria are major cellular sites of reactive oxygen species (ROS) production, and this activity
abnormally increases upon dysfunction of the electron transport chain, as observed in spinal
cord synaptic nerve terminals of SOD1G93A mice [17]. However, PFK3 is known to be
expressed in neurons at low levels due to its efficient targeting to proteasomal degradation by
the E3 ubiquitin ligase anaphase-promoting complex-Cdh1 (APCCdh1) [30]. This could slow
down the AMPK-dependent PFK3 activation, but as we will see the SOD1-induced mitochon-
drial impairment is also likely to promote PFK3 expression.
A rise in ROS production is known to affect the equilibrium of the glutamatergic tripartite
synapses, where astrocytes are known to play an essential role in glutamate removal via EAAT
transporters [31, 32]. Oxidative stress has been shown to affect glutamate clearance from the
synaptic space, thus paving the way to excitotoxic effects mediated by excessive Ca2+ entry into
MNs [33]. It has been shown that one of the consequences of excessive Ca2+ entry is a tissue-
selective aberrant activation of the calpain/calpastatin system [34, 35], which, among its several
targets, leads to cleavage of cyclin-dependent kinase 5 (CDK5) activator p35 into membrane-
bound p10 and cytosolic p25 subunits [36]. The p25 subunit forms a complex with CDK5 that
promotes a deregulated activation of the kinase itself [37], and it has been shown that the
CDK5-p25 complex hyper-phosphorylates Cdh1, thus inhibiting the formation of the APCCdh1
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complex [38, 39]. This has been confirmed in cortical neurons, showing that simulation of
excitotoxicity through N-methyl-D-aspartate receptor activation inhibits CDK5/Cdh1 and
increases cytosolic PFK3 levels, thereby switching the glucose catabolism from PPP to glycoly-
sis [23]. Finally, the enhanced cytosolic Ca2+, induced by excessive glutamate, has been found
to trigger also mitochondrial Ca2+ overload with increased ROS production [40, 41].
Starting from the large amount of evidence described above, we derived a system of three
functional loops strictly intertwined, and developed a mathematical model able to identify the
key hub of the three loops and the related most relevant and critical targets for advanced thera-
peutic solutions in ALS.
Loop system
Loop 1. According to the above evidence, by affecting spinal MN mitochondria, mutant
SOD1 would have the effect of increasing AMPK, activating PFK3, depressing PPP, and reduc-
ing the ability of the cell to counteract oxidative stress, thus leading to further mitochondrial
damage. This triggers a first positive loop that can be schematically represented by an even
number of inhibitory steps and is therefore overall activating: OXPHOS-AMPK-PFK3-PP-
P-OXPHOS (Fig 1A and 1B). This scenario is intriguing because the dynamics of a positive
loop can account for a transition between health and disease [19], while it is also consistent
with the well-known role of oxidative stress in the development of ALS [42, 43].
Loop 2. As described above, data in the literature indicate that APCCdh1 plays a key role in
the regulation of neuronal glucose metabolism by keeping low PFK3 expression, while
APCCdh1 inhibition is expected to produce the opposite effect. This biological pathway can be
connected to part of Loop 1 thereby closing a second loop, PFK3-PPP-GLUTAMA-
TE-APCCdh1-PFK3 (Fig 1A and 1C), containing four inhibitory steps, and therefore being
overall positive or activating. This loop is partially overlapped with the previous one, while
both loops converge on PFK3, one promoting its expression level, and the other its phosphory-
lation. Hence, the two loops can act synergistically by strengthening each other and are
expected to strongly induce the transition from low glycolysis/high PPP, maintaining redox
balance, to high glycolysis/low PPP, leading to redox unbalance and oxidative stress.
Loop 3. As excitotoxicity rise, a third positive loop can be envisaged: OXPHO-
S-AMPK-PFK3-PPP-GLUTAMATE-OXPHOS (Fig 1A and 1D), also partially overlapped
with the previous ones. The abnormal glutamatergic signal triggers an aberrant cytosolic Ca2+
rise in spinal cord motoneurons, with a consequent mitochondria Ca2+ overload and a dra-
matic disruption of the mitochondrial membrane potential (ΔCm). The mitochondrial mem-
brane potential (ΔCm) is an essential component in the process of energy storage (ATP)
during oxidative phosphorylation. The occurrence of inner membrane disruption significantly
compromises the magnitude of ΔCm, thus mitochondrial respiratory chain becomes a signifi-
cant producer of reactive oxygen species (ROS) [44]. The given excessive production of ROS is
again overlapped with the previous two loops and fosters the already compromised pathologi-
cal scenario.
In summary, the herein-described ALS pathogenesis model involves three overlapped posi-
tive loops forming a synergistic system that fuels oxidative stress and excitotoxicity, i.e. two
leitmotifs of the disease at the cellular and molecular levels.
Mathematical model and methods
The dynamics of the loop system (Fig 1) can be studied using mathematical tools from Systems
and Control Theory. We propose a system of differential equations, modeling the dynamical
interactions between pairs of functional agents. We assume that each functional agent, say xi,
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is subject to a spontaneous degradation and evolves with time constant txi . We denote by f an
activation function, which is monotonically increasing in its argument, and by h an inhibition
function, which is monotonically decreasing in its argument. The differential equation
describing the evolution of the generic functional agent xi has therefore the form:
txi _xi þ xi ¼ f ðxjÞ þ hðxkÞ þ � � �
where xj is a functional agent that activates xi, while xk is a functional agent that inhibits xi. The
Fig 1. Diagrams of the feedback loop system involved in ALS pathogenesis in spinal cord motor neurons. (A) Overall diagram of the feedback loop system. Boxes
represent functional agents and arcs the effects that each agent exerts on another one. Mutant SOD1 is the triggering element that, by affecting mitochondria, induces a
dynamical transition in the loop system thereby causing the insurgence of disease. (B, C, D) Diagrams of the three single loops constituting the loop system. AMPK:
AMP-activated kinase; APCCdh1: E3 ubiquitin ligase anaphase-promoting complex-Cdh1; OXPHOS: oxidative phosphorylation; PFK3: 6-phosphofructo-2-kinase/
fructose-2,6-bisphosphatase-3; PPP: pentose phosphate pathway.
https://doi.org/10.1371/journal.pone.0244234.g001
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Since the generic functional agent xk either activates xi or inhibits xi, or has no influence on
xi, the corresponding entry of J is sign determined: sign(Jik)2{+,−,0}.
Common examples of the involved monotonic functions are the well-known Hill functions
[45, 46], having the following expressions:
f xð Þ ¼
axp
1þ bxp
and h xð Þ ¼
g
1þ dxp
for increasing and decreasing functions, respectively, where p is the Hill coefficient and the Greek
letters represent positive real parameters. However, the results we provide here exclusively depend
on the qualitative monotonicity property and do not rely on any assumed exact functional expres-
sions for activations and inhibitions, or on the value of any involved parameter.
To describe the dynamic evolution of the system we denote the concentrations or activities
of the functional agents as follows:
- [mutant SOD1] = u,
- [mitochondrial OXPHOS] = m,
- [AMPK] = a,
- [PFK3] = k,
- [APCCdh1] = c,
- [glutamate] = g,
- [PPP] = p
resulting in the simplified scheme in Fig 2.
Then, the dynamics associated with the feedback loop arrangement (Fig 2) is described by
the following system of ordinary differential equations, where the activating and inhibitory
interactions visualized in Figs 1 and 2 are modelled in terms of monotonic functions:
ta _a þ a ¼ h6ðmÞ ð1Þ
tk
_k þ k ¼ f1ðaÞ þ h4ðcÞ ð2Þ
tc _c þ c ¼ h2ðgÞ ð3Þ
tm _m þm ¼ h7ðuÞ þ h1ðgÞ þ f2ðpÞ ð4Þ
tp _p þ p ¼ h5ðkÞ ð5Þ
tg _g þ g ¼ h3ðpÞ ð6Þ
The dynamic behavior of the loop system can then be qualitatively determined by associat-
ing the equation system with its interaction matrix S, which can be computed as the sign pat-
tern of the system Jacobian matrix J: S = sign(J), where the sign function for matrices is
defined elementwise. In view of the monotonicity of the involved interaction functions, the
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interaction matrix S can be derived exclusively based on the qualitative knowledge about the
system that is summarized in the graphs in Figs 1 and 2, while no information on the involved
functional expressions and parameters is needed. Then, the sign of the loops present in the
graph associated with the signed matrix S can provide useful insight into the system’s behavior:
as shown in [19], if all the loops are positive, then the system is a candidate multistationary sys-
tem, hence it can admit multiple stable equilibria corresponding to different configurations.
A functional agent can influence another not only directly, but also indirectly. For instance,
in Fig 2 we see that p activates m directly, but it also inhibits g that in turn inhibits m. How can
we compute a net interaction matrix, which takes into account the resulting effect of all possi-
ble direct and indirect influences between pairs of functional agents? To display the overall net
signed effect of each functional agent on each of the others, when the system is perturbed
around a stable equilibrium point, we can compute the structural influence matrix according
to the methods proposed in [47]. The structural influence matrix can be computed in closed
form as the sign pattern of the adjoint of the negative Jacobian matrix, sign[adj(−J)]; equiva-




















Fig 2. Graph associated with the system of differential Eqs (1)-(6). The functional agents shown in Fig 1 are denoted as [mutant SOD1] =u, [OXPHOS] = m, [AMPK] =
a, [PFK3] = k, [APCCdh1] = c, [GLUTAMATE] = g, and [PPP] = p, while their interactions are associated with activation functions f and inhibition functions h. Arcs as in
Fig 1.
https://doi.org/10.1371/journal.pone.0244234.g002
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where Ri is a row vector that has a one entry in position i and is zero elsewhere, while Ck is a
column vector that has a one entry in position k and is zero elsewhere. Since we assume stabil-
ity of the equilibrium, we have det(−J)>0, hence we can equivalently consider
sign det




Each entry of the structural influence matrix can be either ‘+’, if the net overall influence is
always positive regardless of the system parameters; ‘–’, if the net overall influence is always
negative regardless of the system parameters; ‘0’ if the net overall influence is always zero
regardless of the system parameters; or ‘?’ if the net overall influence can have a different sign
depending on the system parameters (for instance, this happens if functional agent A directly
inhibits functional agent C, but at the same time activates functional agent B that in turn acti-
vates C: then, we have two contrasting effects, a direct inhibition and an indirect activation,
and depending on the numerical strength of the interactions the overall net effect can be either
positive or negative). Efficient approaches for computing the structural influence matrix are
proposed in [47] for a vast class of systems, including (1)-(6).
Results
The system (1)-(6), which describes the dynamic evolution of the functional agents involved in
ALS pathogenesis, can be associated with two signed matrices, as discussed in the “Mathemati-
cal model and methods” section. The first is the interaction matrix S, shown in Equation (7),
which displays the direct influence of each functional agent on each of the others. Matrix S
includes the signs of the entries of the system Jacobian matrix (activation functions lead to a
‘+’ sign, while inhibition functions lead to a ‘–’, and no interaction leads to a ‘0’):
In addition, Su is the signed input matrix (8), which includes the signs of the derivatives of
the system equations with respect to the “triggering input” u (mutant SOD1):
As already observed, three loops are present in the system and they are all positive, because
include an even number of inhibitory (i.e., negative) interactions. These loops can be easily
Direct influence of: AMPK PFK3 APCCdh1 OXPHOS PPP GLUTAMATE
on AMPK − 0 0 − 0 0
on PFK3 + − − 0 0 0
S = on APCCdh1 0 0 − 0 0 − (7)
on OXPHOS 0 0 0 − + −
on PPP 0 − 0 0 − 0
on GLUTAMATE 0 0 0 0 − −
https://doi.org/10.1371/journal.pone.0244234.t001
Direct influence of: mutant SOD1
on AMPK 0
on PFK3 0
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visualized by inspecting matrix S (7) as well as the graph in Figs 1 and 2. The first loop is m−a
−k−p−m (Fig 1B), the second is k−p−g−c−k (Fig 1C), and the third is m−a−k−p−g−m (Fig 1D).
Because only positive loops are present in the associated graph, this is a candidate multista-
tionary (bistable) system according to the results in [19]. As a consequence, its Jacobian matrix
has a dominant eigenvalue that is real; this entails that an equilibrium can become unstable
exclusively due to a real eigenvalue that crosses the imaginary axis, turning from negative to
positive. This type of instability is typically associated with a bifurcation leading to the destabi-
lization of one equilibrium and the concurrent appearance of additional stable equilibria. In
our system, among the stable equilibria one corresponds to “healthy condition” and another to
“pathological condition”, explaining the possible onset of the disease.
Since all the loops are positive, we can show that the system in Eqs (1)–(6) is a monotone
system, i.e. its Jacobian matrix can be turned into a Metzler matrix (i.e., a matrix with nonneg-
ative off-diagonal entries) by changing the sign of some variables. In fact, changing the sign of
the variables a, k, and g leads to the new signed matrices:
and
where clearly Ŝ (9) is a Metzler matrix (all its off-diagonal entries are nonnegative). Being
the system monotone, oscillatory instability can be ruled out: either the system has a single sta-
ble equilibrium point, or one equilibrium can be unstable in the presence of two coexisting sta-
ble equilibria (e.g. one “healthy” and one “pathological”).
In particular, we can think of a scenario with two qualitative stable equilibria: if u (mutant
SOD1) is at a high level, then it contributes to keep m (OXPHOS) low, which keeps a (AMPK)
high, which keeps k (PFK3) high as well, which keeps p (PPP) low (which contributes to keep
m low, consistently), and this keeps g (glutamate) high (which also consistently keeps m low),
which keeps c (APCCdh1) low, which consistently keeps k high. On the other hand, if u is at a
low level, then it contributes to keep m high, which keeps a low, which keeps k low as well,
which keeps p high (which consistently contributes to keep m high), and this keeps g low
(which also consistently keeps m high), which keeps c high, which consistently keeps k low.
Both equilibria are stable (all the activations and inhibitions are consistent, so that there
cannot be oscillations, which could only happen in the presence of negative feedback loops, i.e.
Direct influence of: −AMPK -PFK3 APCCdh1 OXPHOS PPP −GLUTAMATE
on −AMPK − 0 0 + 0 0
on −PFK3 + − + 0 0 0
Ŝ ¼ on APCCdh1 0 0 − 0 0 + (9)
on OXPHOS 0 0 0 − + +
on PPP 0 + 0 0 − 0
on −GLUTAMATE 0 0 0 0 + −
https://doi.org/10.1371/journal.pone.0244234.t003
Direct influence of: mutant SOD1
on −AMPK 0
on −PFK3 0
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loops with an odd number of inhibitions, as shown in [19]) and a variation in the input u,
which is associated with mutant SOD1, can induce a transition from one stable steady state to
the other.
We can assess the effect of an input perturbation on the steady state of the system, and the
ensuing steady-state variation, with the qualitative, parameter-free approach for the computa-
tion of structural influence matrices previously outlined in [47]. In particular, if we assume sta-
bility of the equilibrium at which the system is resting, the effect of a sudden increase in the
value of u on the value of the variables (a, k, c, m, p, g) can be captured by the structural input-
output influence matrix:
where the ‘+’ entries mean that the new steady-state value of variables a, k and g always
increases, while the ‘−’ entries mean that the new steady-state value of variables c, m and p
always decreases, if the value of u suddenly increases, regardless of the expressions for the acti-
vation and inhibition functions and regardless of parameter values.
More in general, we can compute the structural influence matrix (12), whose (i, k) entry
expresses the structural sign of the variation in the steady state of the ith variable due to the
addition of a persistent input acting on the equation of the kth variable. For the considered sys-
tem, if we assume stability of the equilibrium, the structural influence matrix turns out to be:
In this case, computing the structural influence matrix is straightforward if we notice that
the Jacobian matrix S (7) can be turned into a Metzler matrix by changing the sign of the first,
second and sixth variable. In fact, as proven in [47], for a stable Metzler matrix that is also irre-
ducible, as is the case for the Metzler matrix Ŝ (9), the structural influence matrix has all posi-
tive entries. Then, we can obtain the structural influence matrix for our system by considering
a fully positive sign matrix and changing sign to the first, second and sixth row and column,
which leads to the structural influence matrix (12) shown above.
Differently from the signed interaction matrix S, which is associated with the sign pattern
of the Jacobian matrix and therefore expresses the direct signed influence of each functional
agent on each of the others (so that the matrix entries correspond to the inhibiting/activating
arcs in Figs 1 and 2), the influence matrix captures the overall net signed influence, which
results from the combination of direct and several indirect effects through different entangled
Overall influence of: mutant SOD1
on AMPK +
on PFK3 +





Overall influence of: AMPK PFK3 APCCdh1 OXPHOS PPP GLUTAMATE
on AMPK + + − − − +
on PFK3 + + − − − +
on APCCdh1 − − + + + − (12)
on OXPHOS − − + + + −
on PPP − − + + + −
on GLUTAMATE + + − − − +
https://doi.org/10.1371/journal.pone.0244234.t006
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loops and paths. Note that the fourth column of the structural influence matrix (12) corre-
sponds to the negative of the structural input-output influence matrix (11), exactly because
input u acts, with a negative (inhibiting) direct influence, upon the fourth variable, m. Interest-
ingly, we can notice that all the net overall influences among functional agents in the consid-
ered system are structurally signed, regardless of parameter values.
The achievement of our aim is demonstrated by the following clues, originating from the
mathematical model: all the three loops in the system share precisely one interaction, which is
the inhibition of p due to k, h5(k). If this single interaction is knocked out, then there are no
more loops in the system, and in this case there is a single equilibrium, which must be stable.
In fact, by inspecting system (1)-(6) we can notice that, if h5(k) = 0, then, for a given value of
the input �u, the values of the variables at steady state can be directly computed as �p ¼ 0; �g ¼
h3ð0Þ; �c ¼ h2ðh3ð0ÞÞ; �m ¼ h7ð�uÞ þ h1ðh3ð0ÞÞ þ f2ð0Þ; �a ¼ h6ð �mÞ and �k ¼ f1ð�aÞ þ h4ð�cÞ,
hence a single equilibrium is possible. This highlights the importance of the inhibitory interac-
tion from PFK3 to PPP, which looks crucial to allow bistability, hence the possibility of having
both a healthy stable state and a pathological stable state, depending on the initial conditions
and on the input u due to mutant SOD1.
Bistability is possible after crossing a bifurcation point due to the variation of a bifurcation
parameter (see Fig 3), which in our loop system can be identified with the strength of the inter-
action between PFK3 and PPP, i.e. the key interaction of the system, corresponding to the
parameter h5(k) in the differential equations. At the beginning of the pathogenic process, the
disturbing action of misfolded SOD1 on mitochondria with AMPK activation is followed by a
phosphorylation of PFK3 that modifies its enzymatic kinetics [29, 48]. Hence, even if PFK3 is
still expressed at low levels, its phosphorylation strengthens the negative interaction between
PFK3 and PPP. We assume that this is the event that drives the system to undergo a bifurcation
and exhibit bistability (Fig 3). Then, the continuous disturbing input of SOD1, and the consis-
tent monotone action of the functional loop agents, can drive the system to fall onto the stable
equilibrium point that represents the pathological condition (Fig 3). Thereafter, if the action of
SOD1 further strengthens the key interaction corresponding to h5(k), the system could cross a
second, inversely oriented bifurcation point, hence leaving the bistability zone and remaining
positioned at the unique “pathological” equilibrium point (Fig 3). This bifurcation diagram
can be achieved by assuming function h5(k) of the form
h5ðkÞ ¼ mhðkÞ;
where h is a given decreasing function and μ is a positive strength parameter. Due to monoto-
nicity, the value of PFK3 in the stable equilibria (the green ones in Fig 3) is an increasing func-
tion of μ.
Discussion
Our pathogenesis model of ALS follows a completely new approach based on Systems and
Control Theory. The model embodies some of the most accredited driving factors of the
pathology, including mitochondria, oxidative stress and excitotoxicity. The main novelty is
that these factors are entangled in a system of feedback loops according to their mutual inter-
actions. The onset and progression of the disease is explained as a transition from one equilib-
rium point (health) to another one (disease), which can occur in positive loop systems upon
the influence of an external stimulus. In our model, constructed on SOD1 mutants, the stimu-
lus is assumed to be a damaging action of misfolded SOD1 proteins on mitochondria, which is
also the rationale for adopting the mitochondria/glycolysis loop as the core of the model,
among a number of possible etiological anomalies reported in the literature [49].
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The model consists of three positive loops coupled together and acting synergistically, i.e.
any loop serves as a sensitization agent for each other, which involves their mutual strengthen-
ing and, as generally experienced for these dynamical systems, can lead to the irreversibility of
Fig 3. Bifurcation diagram (top panel) and corresponding potential energy diagrams (bottom panels). Diagrams represent the evolution of the equilibrium points of the
loop system in a phase space consisting of all possible values of PFK3 enzyme activity and of a bifurcation parameter, which is taken as the strength of the interaction
between PFK3 and PPP (i.e. term h5(k) in the differential equations, see text and Fig 2). Due to SOD1-induced AMPK activation, PFK3 is phosphorylated, the
interaction strengthens, and the system undergoes a bifurcation and becomes multistationary: two stable equilibrium points (eq.0 and Eq 2, green lines) and an unstable
one (Eq 1, red line) coexist. Thereafter, the continuous disturbing action of SOD1 (h7(u), see Fig 2) induces an increase in PFK3 activity that drives the loop system to
the stable equilibrium point (Eq 2) that represents the pathological condition. Finally, a further strengthening of the PFK3/PPP interaction could induce the system to
leave the multistationary region, by crossing an inversely oriented bifurcation point, and remain positioned at the unique “pathological” equilibrium point.
https://doi.org/10.1371/journal.pone.0244234.g003
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their transition [50]. We invoke bifurcation dynamics to explain the occurrence of mutistatio-
narity, involving the interaction between mitochondrial-induced alteration of glycolysis/PPP
ratio (Fig 1B) with excitotoxicity (Fig 1C and 1D). These events occur in a very early phase of
the disease and direct evidence of their relative timing is lacking. However, unbalance of mito-
chondrial function and enhanced glucose metabolism have been recorded at an early pre-
symptomatic stage in spinal cord MNs of SOD1G93A mice [17, 18]. These events possibly open
the way to the wide complex of phenomena that have been described in ALS, involving not
only MN degeneration, but also astrogliosis, microglia activation and neuroinflammation.
The core of the model is tailored on MNs and bases on data obtained from the SOD1G93A
mice model, but it can be extended to other forms of familial ALS, since different SOD1 muta-
tions and other proteins linked to the disease, like TDP-43, FUS, and C9ORF72, have been
found to cause mitochondrial defects and disruption of the energy metabolism in MNs [51–
53], hence potentially eliciting the same system of loops. Also, the role of the ATP/AMP ratio
can explain a hitherto unsolved feature of ALS in SOD1G93A and SOD1G85R mice, i.e. the cor-
relation between neuron size and degeneration, with largest fast-twitch fatigable (FF) MNs
being the first to be affected, followed by fast-twitch, fatigue-resistant (FR) MNs, and finally by
slow-twitch (S) MNs [54, 55]. FF MNs are the largest ones, and it has been shown that they
consume more ATP per action potential to maintain cytosolic Na+ and K+ homeostasis, which
makes them more sensitive to ATP depletion caused by mitochondrial dysfunction [56]. Our
model provides a prompt explanation for these data, because a more rapid alteration of the
ATP/AMP ratio in FF MNs would accelerate the triggering of the pathogenetic loop system.
We are aware that, although our loops cover major etiopathological mechanisms of ALS,
other mechanisms have been suggested to play a role in pathogenesis, such as deficits in axonal
transport [7], endoplasmic reticulum stress, and proteostasis [57]. However, in mutant forms of
the disease the two latter points are correlated to misfolded protein accumulation within mito-
chondria, thus being, to some extent, embodied in our model. Apart from speculation whether
our model is exhaustive or not, the significant result of our approach is having arranged a wide
set of data into a system of loops whose dynamics can account for the transition that generates
the disease. Hence, the loop systems can be used as a dynamic map for the identification of
druggable targets whose treatment could be allegedly able to block this transition.
As shown by the above structural influence matrix (12), the elements of our loop system
can be divided into two synergistic groups that either promote (AMPK, GLUTAMATE,
PFK3) or prevent (OXPHOS, PPP, APCCdh1) the pathogenic status. Such a result provides a
clear indication for the development of possible therapeutic treatments. However, the interac-
tion involving PFK3 and the PPP pathway is the most critical, as its deletion would disrupt
multistationarity in the system, suggesting that its targeting could be sufficient to prevent the
transition from physiological to pathological condition. Therefore, according to this model,
the best druggable targets should be sought inside the complex of mechanisms that modulate
PFK3 levels within MNs, aimed at maintaining low cellular level and activity of this enzyme
system. A validation of this assumption could be obtained by exploiting in-vitro, ex-vivo, or
even in-vivo models from SOD1G93A mice, using specific readouts downstream the target after
manipulations aimed at reducing the PFK3 levels. The envisaged crucial role of PFK3 could
also explain the lifetime of disease insurgence. As said above, PFK3 is maintained at low levels
in neurons due to targeting to proteasomal degradation, which in our model represents a leak-
age out of the loop system. This is likely to slow down the transition of the system that gives
rise to neurodegeneration and becomes eventually manifest at the symptomatic phase of the
disease.
Finally, an added value of the proposed mathematical system is the possibility of extending
our approach to other CNS pathologies, like Alzheimer or Parkinson’s diseases that share
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various neurotoxic mechanisms with ALS, including mitochondrial damage, oxidative stress,
and excitotoxicity [58, 59]. In this respect, it is notable that the role of a positive feedback loop
has been envisaged for Alzheimer [60], while elements of our loop system, like hyper-glycolysis
and mitochondrial dysfunction, are also part of a post-concussion, neurometabolic dysfunc-
tion model [61]. This suggests that our loop model, possibly with suitable modifications, could
profitably indicate new druggable targets for neurodegenerative and neurometabolic diseases,
or that different diseases could share the same targets.
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